Radiological biomarkers for diagnosis in PSP

Where are we and where do we need to be?

for the Movement Disorder Society-Endorsed PSP Study Group

Research output: Contribution to journalReview article

49 Citations (Scopus)

Abstract

PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field.

Original languageEnglish (US)
Pages (from-to)955-971
Number of pages17
JournalMovement Disorders
Volume32
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Biomarkers
Neuroimaging
Progressive Supranuclear Palsy
Corpus Striatum
National Institute of Neurological Disorders and Stroke
Primary Spontaneous Pneumothorax
Tauopathies
Pathology
Diffusion Tensor Imaging
Fluorodeoxyglucose F18
Single-Photon Emission-Computed Tomography
Research
PubMed
Brain Stem
Atrophy
Autopsy
Dopamine
Databases
Ligands

Keywords

  • diagnosis
  • magnetic resonance imaging
  • positron emission tomography
  • progressive supranuclear palsy
  • single-photon emission computed tomography

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Radiological biomarkers for diagnosis in PSP : Where are we and where do we need to be? / for the Movement Disorder Society-Endorsed PSP Study Group.

In: Movement Disorders, Vol. 32, No. 7, 01.07.2017, p. 955-971.

Research output: Contribution to journalReview article

for the Movement Disorder Society-Endorsed PSP Study Group 2017, 'Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?', Movement Disorders, vol. 32, no. 7, pp. 955-971. https://doi.org/10.1002/mds.27038
for the Movement Disorder Society-Endorsed PSP Study Group. / Radiological biomarkers for diagnosis in PSP : Where are we and where do we need to be?. In: Movement Disorders. 2017 ; Vol. 32, No. 7. pp. 955-971.
@article{e50d5f6bd15144c19678975b16bf1ebc,
title = "Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?",
abstract = "PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field.",
keywords = "diagnosis, magnetic resonance imaging, positron emission tomography, progressive supranuclear palsy, single-photon emission computed tomography",
author = "{for the Movement Disorder Society-Endorsed PSP Study Group} and Whitwell, {Jennifer Lynn} and H{\"o}glinger, {G{\"u}nter U.} and Angelo Antonini and Yvette Bordelon and Boxer, {Adam L.} and Carlo Colosimo and {van Eimeren}, Thilo and Golbe, {Lawrence I.} and Jan Kassubek and Carolin Kurz and Irene Litvan and Alexander Pantelyat and Gil Rabinovici and Gesine Respondek and Axel Rominger and Rowe, {James B.} and Maria Stamelou and Josephs, {Keith Anthony}",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/mds.27038",
language = "English (US)",
volume = "32",
pages = "955--971",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Radiological biomarkers for diagnosis in PSP

T2 - Where are we and where do we need to be?

AU - for the Movement Disorder Society-Endorsed PSP Study Group

AU - Whitwell, Jennifer Lynn

AU - Höglinger, Günter U.

AU - Antonini, Angelo

AU - Bordelon, Yvette

AU - Boxer, Adam L.

AU - Colosimo, Carlo

AU - van Eimeren, Thilo

AU - Golbe, Lawrence I.

AU - Kassubek, Jan

AU - Kurz, Carolin

AU - Litvan, Irene

AU - Pantelyat, Alexander

AU - Rabinovici, Gil

AU - Respondek, Gesine

AU - Rominger, Axel

AU - Rowe, James B.

AU - Stamelou, Maria

AU - Josephs, Keith Anthony

PY - 2017/7/1

Y1 - 2017/7/1

N2 - PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field.

AB - PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field.

KW - diagnosis

KW - magnetic resonance imaging

KW - positron emission tomography

KW - progressive supranuclear palsy

KW - single-photon emission computed tomography

UR - http://www.scopus.com/inward/record.url?scp=85018927746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018927746&partnerID=8YFLogxK

U2 - 10.1002/mds.27038

DO - 10.1002/mds.27038

M3 - Review article

VL - 32

SP - 955

EP - 971

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 7

ER -